Fecal Microbiota Transplantation in Inflammatory Bowel Disease: Beyond the Excitement
Open accessThe DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Abstract
The purpose of this article is to perform a systematic review of the literature on the use of fecal microbiota transplantation (FMT) in inflammatory bowel disease (IBD).There is an increasing interest of both physicians and patients in assessing the possible role of the FMT in the treatment of IBD.Electronic and manual bibliographic searches were performed to identify original reports in which subjects with IBD were treated with FMT. Because of the scarcity of studies with adequate sample size, case series and case reports were also considered. A critical appraisal of the clinical research evidence on the effectiveness, safety, and other parameters related to FMT was made. Data extraction was independently performed by 2 reviewers.We found a total of 31 publications on the use of FMT in IBD. The majority were case reports or case series, whereas 8 publications reported data from open-label trials including a very less number of patients. A total of 133 patients with IBD were managed with FMT. Of these, 57 subjects (43%) had a Clostridium difficile infection. A resolution or reduction of symptoms was reported in 80 of 113 (71%) patients with evaluable IBD. Moreover, FMT does not seem to provide the same safety profile showed for non-IBD individuals with C difficile infection.The available evidence is limited and weak. FMT has the potential to be somehow of help in managing patients with IBD, but considerable further efforts are necessary to make this procedure a valid option for these subjects.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Duodenal Infusion of Donor Feces for Recurrent Clostridium difficile
van Nood, E., Vrieze, A., Nieuwdorp, M., Fuentes, S., Zoetendal, E. G., de Vos, W. M., Visser, C. E., Kuijper, E. J., Bartelsman, J. F. W. M., Tijssen, J. G. P., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1205037 · Cited by 3,708 · cited 1×
“This finding seems to be well below than that found in the non-IBD individuals with C difficile infection (92%).(7,56) The evaluation of the impact of FMT on other outcomes, such as the achievement of clinical remission or its effect on IBD-specific treatment, as well as a distinction of UC and CD, is not currently po…”
ResultVrieze, A., Van Nood, E., Holleman, F., Salojärvi, J., Kootte, R. S., Bartelsman, J. F. W. M., Dallinga–Thie, G. M., Ackermans, M. T., Serlie, M. J., Oozeer, R., et al. (2012) · Gastroenterology · doi:10.1053/j.gastro.2012.06.031 · Cited by 2,913
The gut flora as a forgotten organ
O'Hara, A. M., & Shanahan, F. (2006) · The EMBO Reports · doi:10.1038/sj.embor.7400731 · Cited by 2,791
Microbial Influences in Inflammatory Bowel Diseases
Sartor, R. B. (2008) · Gastroenterology · doi:10.1053/j.gastro.2007.11.059 · Cited by 1,927
Manichanh, C., Borruel, N., Casellas, F., & Guarner, F. (2012) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2012.152 · Cited by 1,160 · cited 1×
“However, it is not yet clear if dysbiosis is a possible cause or an epiphenomenon of the disease.(15) At present, almost all effective therapies (such as aminosalicylates, steroids, immunosuppressants, and biologics) are targeted toward the inflammatory and/or immunological component of the disease, and gut microbiota…”
BackgroundDysbiosis of the faecal microbiota in patients with Crohn’s disease and their unaffected relatives
Joossens, M., Huys, G., Cnockaert, M., De Preter, V., Verbeke, K., Rutgeerts, P., Vandamme, P., & Vermeire, S. (2011) · Gut · doi:10.1136/gut.2010.223263 · Cited by 1,063
Willing, B. P., Dicksved, J., Halfvarson, J., Andersson, A. F., Lucio, M., Zheng, Z., Järnerot, G., Tysk, C., Jansson, J. K., & Engstrand, L. (2010) · Gastroenterology · doi:10.1053/j.gastro.2010.08.049 · Cited by 1,032
Treating Clostridium difficile infection with fecal microbiota transplantation
Bakken, J. S., Borody, T., Brandt, L. J., Brill, J. V., Demarco, D. C., Franzos, M. A., Kelly, C., Khoruts, A., Louie, T., Martinelli, L. P., et al. (2011) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2011.08.014 · Cited by 1,003
Kassam, Z., Lee, C. H., Yuan, Y., & Hunt, R. H. (2013) · American Journal of Gastroenterology · doi:10.1038/ajg.2013.59 · Cited by 904
Therapeutic Potential of Fecal Microbiota Transplantation
Smits, L. P., Bouter, K. E. C., de Vos, W. M., Borody, T. J., & Nieuwdorp, M. (2013) · Gastroenterology · doi:10.1053/j.gastro.2013.08.058 · Cited by 717
Fecal microbiota transplantation and emerging applications
Borody, T. J., & Khoruts, A. (2012) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2011.244 · Cited by 677 · cited 1×
“INTRODUCTION Fecal microbiota transplantation (FMT), also known as “fecal bacteriotherapy” or “fecal infusion,” consists in the injection (by various routes: nasogastric or nasojejunal tube, upper endoscopy, retention enema, colonoscopy) of a liquid filtrate of feces from healthy donor into the gastrointestinal tract…”
BackgroundMucus Enhances Gut Homeostasis and Oral Tolerance by Delivering Immunoregulatory Signals
Shan, M., Gentile, M., Yeiser, J. R., Walland, A. C., Bornstein, V. U., Chen, K., He, B., Cassis, L., Bigas, A., Cols, M., et al. (2013) · Science · doi:10.1126/science.1237910 · Cited by 642
Advances in inflammatory bowel disease pathogenesis: linking host genetics and the microbiome
Knights, D., Lassen, K. G., & Xavier, R. J. (2013) · Gut · doi:10.1136/gutjnl-2012-303954 · Cited by 468 · cited 1×
“As shown by concordance studies in monozygotic twins, genetic factors have only a partial role in the development of the disease, and almost all genes linked to IBD are related to mucosal immunity.(11,12) Among environmental factors, alteration of gut microbiota is known to be deeply involved in the pathogenesis of IB…”
BackgroundCammarota, G., Ianiro, G., & Gasbarrini, A. (2014) · Journal of Clinical Gastroenterology · doi:10.1097/mcg.0000000000000046 · Cited by 428
Self-citationMattila, E., Uusitalo–Seppälä, R., Wuorela, M., Lehtola, L., Nurmi, H., Ristikankare, M., Moilanen, V., Salminen, K., Seppälä, M., Mattila, P. S., et al. (2012) · Gastroenterology · doi:10.1053/j.gastro.2011.11.037 · Cited by 371
Angelberger, S., Reinisch, W., Makristathis, A., Lichtenberger, C., Dejaco, C., Papay, P., Novacek, G., Trauner, M., Loy, A., & Berry, D. (2013) · American Journal of Gastroenterology · doi:10.1038/ajg.2013.257 · Cited by 330 · cited 2×
“Most of these were case reports or case series, whereas 8 publications reported data from open-label trial with a small number of patients treated.(23,31,37,38,43,46,49,50) Really, from the study of Grehan et al,(23) only 1 patient had IBD of a total of 10 patients treated in a small open-label trial.”
BackgroundResultKunde, S., Pham, A., Bonczyk, S., Crumb, T., Duba, M., Conrad, H., Cloney, D., & Kugathasan, S. (2013) · Journal of Pediatric Gastroenterology and Nutrition · doi:10.1097/mpg.0b013e318292fa0d · Cited by 314 · cited 1×
“Most of these were case reports or case series, whereas 8 publications reported data from open-label trial with a small number of patients treated.(23,31,37,38,43,46,49,50) Really, from the study of Grehan et al,(23) only 1 patient had IBD of a total of 10 patients treated in a small open-label trial.”
BackgroundTreatment of ulcerative colitis by implantation of normal colonic flora
Bennet, J., & Brinkman, M. (1989) · The Lancet · doi:10.1016/s0140-6736(89)91183-5 · Cited by 304
Kump, P. K., Gröchenig, H.-P., Lackner, S., Trajanoski, S., Reicht, G., Hoffmann, K. M., Deutschmann, A., Wenzl, H. H., Petritsch, W., Krejs, G. J., et al. (2013) · Inflammatory Bowel Diseases · doi:10.1097/mib.0b013e31829ea325 · Cited by 235 · cited 1×
“Most of these were case reports or case series, whereas 8 publications reported data from open-label trial with a small number of patients treated.(23,31,37,38,43,46,49,50) Really, from the study of Grehan et al,(23) only 1 patient had IBD of a total of 10 patients treated in a small open-label trial.”
BackgroundBorody, T. J., George, L., Andrews, P., Brandl, S., Noonan, S., Cole, P., Hyland, L., Morgan, A., Maysey, J., & Moore‐Jones, D. (1989) · Medical Journal of Australia · doi:10.5694/j.1326-5377.1989.tb136704.x · Cited by 221
De Leon, L. M., Watson, J. B., & Kelly, C. R. (2013) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2013.04.045 · Cited by 215 · cited 2×
“Notably, serious adverse events, such as bacteremia and transient relapse of previously quiescent UC, were reported in patients with IBD undergoing FMT for C difficile infection.(40,44) DISCUSSION FMT represents a promising therapeutic option for the restoration of disrupted intestinal microbiota, although the studies…”
ResultChambers, D., Rodgers, M., & Woolacott, N. (2009) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2008.12.010 · Cited by 121 · cited 1×
“The 8 quality items provided by the Centre for Reviews and Dissemination checklist for appraising the quality of case series studies were used to examine each study (Table 2).(22) We considered all reports including at least 3 patients treated with FMT as “case series.”
MethodRussell, G. H., Kaplan, J. L., Youngster, I., Baril‐Dore, M., Schindelar, L., Hohmann, E., & Winter, H. S. (2014) · Journal of Pediatric Gastroenterology and Nutrition · doi:10.1097/mpg.0000000000000283 · Cited by 64
Vermeire, S., Joossens, M., Verbeke, K., Hildebrand, F., Machiels, K., Van den Broeck, K., Van Assche, G., Rutgeerts, P. J., & Raes, J. (2012) · Gastroenterology · doi:10.1016/s0016-5085(12)61356-0 · Cited by 63
Landy, J., Al-Hassi, H. O., Mann, E. R., Peake, S. T., McLaughlin, S. D., Ciclitira, P. J., Clark, S. K., Knight, S. C., & Hart, A. L. (2013) · Gastroenterology · doi:10.1016/s0016-5085(13)63341-7 · Cited by 19
Cited by
Current Understanding of Dysbiosis in Disease in Human and Animal Models
DeGruttola, A. K., Low, D., Mizoguchi, A., & Mizoguchi, E. (2016) · Inflammatory Bowel Diseases · doi:10.1097/mib.0000000000000750 · Cited by 1,122
“IBD.”
BackgroundInfluentialAn omics-based framework for assessing the health risk of antimicrobial resistance genes
Zhang, A.-N., Gaston, J. M., Dai, C. L., Zhao, S., Poyet, M., Groussin, M., Yin, X., Li, L.-G., van Loosdrecht, M. C. M., Topp, E., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-25096-3 · Cited by 939
Factors affecting the composition of the gut microbiota, and its modulation
Hasan, N., & Yang, H. (2019) · PeerJ · doi:10.7717/peerj.7502 · Cited by 755
Shen, Z.-H., Zhu, C.-X., Quan, Y.-S., Yang, Z.-Y., Wu, S., Luo, W.-W., Tan, B., & Wang, X.-Y. (2018) · World Journal of Gastroenterology · doi:10.3748/wjg.v24.i1.5 · Cited by 646
Cammarota, G., Ianiro, G., Kelly, C. R., Mullish, B. H., Allegretti, J. R., Kassam, Z., Putignani, L., Fischer, M., Keller, J. J., Costello, S. P., et al. (2019) · Gut · doi:10.1136/gutjnl-2019-319548 · Cited by 506
Self-citation
Metadata
- Authors
- Ianiro, G., Bibbò, S., Scaldaferri, F., Gasbarrini, A., & Cammarota, G.
- Venue
- Medicine
- Published
- 2014-10
- Volume
- 93
- Issue
- 19
- Pages
- e97
- ISSN
- 0025-7974 (ISSN-L)
- OpenAlex
- W2007293537
- Cited by
- 98
- References
- 25
- FWCI
- 7.13
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.